Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allurion Technologies Total Payout Ratio Related Terms
Allurion Technologies Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for Allurion Technologies's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALUR vs ESMC, LUDG, AEMD: Total Payout Ratio Comparison
For the Medical Devices subindustry, Allurion Technologies's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies Total Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allurion Technologies (ALUR) has a Total Payout Ratio of 0.13 as of Sep. 09, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Allurion Technologies and its competitors.
Is Allurion Technologies' Total Payout Ratio too high?
Allurion Technologies' current Total Payout Ratio is 0.13. Overall, Allurion Technologies has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' Total Payout Ratio compare to ESMC and LUDG?
Allurion Technologies' Total Payout Ratio of 0.13 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Devices & Instruments company?
A good Total Payout Ratio depends on the Medical Devices & Instruments industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Allurion Technologies and its competitors. Allurion Technologies's current Total Payout Ratio is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALUR) is currently considered Possible Value Trap. The stock's GF Value™ is $10.24, compared to a current price of $1.28 — trading 87.5% below its estimated fair value. The current Total Payout Ratio is 0.13. Allurion Technologies' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Allurion Technologies (ALUR), the current Total Payout Ratio is 0.13 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allurion Technologies (ALUR) Overvalued in 2026?
Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued.
The current stock price of $1.28 is trading 87.5% below its estimated GF Value™ of $10.24.
GuruFocus considers Allurion Technologies to be Possible Value Trap.
Key valuation signals for ALUR:
Total Payout Ratio: 0.13
GF Value™: $10.24 vs. price of $1.28 (87.5% below fair value)
No single metric tells the full story. See the ALUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
23GF Score
Get the complete analysis for ALUR
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALUR has been successfully added to your 
